References
- Novak SN, Pearson CM. Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 1971;284:938–42.
- Jayne D. Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol 2010;21:14–17.
- Lovric S, Erdbryegger U, Kumpers P, Woywodt A, Koenecke C, Wedemeyer H, . Rituximab as rescue therapy in anti-neutrophil cytoplasmatic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24:179–85.
- Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, . A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156–68.
- Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, . Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671–8.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
- Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.
- Segelmark M, Phillips BD, Hogan SL, Falk RJ, Jennette JC. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol 2003;10:769–74.
- Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189–91.
- Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, . Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol 2004;83:58–60.
- Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–20.
- Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, . Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255–62.